| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 223 | 2024 | 3695 | 27.840 |
Why?
|
| Antirheumatic Agents | 146 | 2024 | 1335 | 24.410 |
Why?
|
| Osteoporosis | 73 | 2023 | 1581 | 9.820 |
Why?
|
| Rheumatology | 42 | 2023 | 576 | 9.430 |
Why?
|
| Bone Density Conservation Agents | 34 | 2023 | 774 | 7.070 |
Why?
|
| Gout | 23 | 2023 | 556 | 6.190 |
Why?
|
| Methotrexate | 35 | 2023 | 1720 | 6.080 |
Why?
|
| Rheumatic Diseases | 31 | 2023 | 590 | 5.430 |
Why?
|
| Diphosphonates | 25 | 2023 | 625 | 5.290 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 51 | 2019 | 2276 | 4.950 |
Why?
|
| Cardiovascular Diseases | 76 | 2024 | 15108 | 4.100 |
Why?
|
| Arthritis | 19 | 2022 | 658 | 4.020 |
Why?
|
| Bone Density | 34 | 2023 | 3469 | 3.960 |
Why?
|
| Fractures, Bone | 30 | 2020 | 1945 | 3.570 |
Why?
|
| Medication Adherence | 31 | 2023 | 2055 | 3.560 |
Why?
|
| Tumor Necrosis Factor-alpha | 44 | 2023 | 4414 | 3.510 |
Why?
|
| Women's Health | 13 | 2023 | 2034 | 3.220 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 19 | 2017 | 320 | 3.220 |
Why?
|
| Osteoarthritis | 23 | 2022 | 1034 | 3.030 |
Why?
|
| Teriparatide | 5 | 2020 | 225 | 2.920 |
Why?
|
| Biological Products | 21 | 2023 | 856 | 2.870 |
Why?
|
| Registries | 36 | 2023 | 8077 | 2.780 |
Why?
|
| Gout Suppressants | 8 | 2021 | 160 | 2.630 |
Why?
|
| Pharmacoepidemiology | 13 | 2021 | 323 | 2.560 |
Why?
|
| Aged | 316 | 2024 | 162944 | 2.430 |
Why?
|
| Middle Aged | 321 | 2024 | 213127 | 2.370 |
Why?
|
| Colchicine | 6 | 2016 | 242 | 2.330 |
Why?
|
| Female | 442 | 2024 | 379592 | 2.270 |
Why?
|
| Humans | 644 | 2024 | 742088 | 2.160 |
Why?
|
| Male | 395 | 2024 | 349538 | 2.060 |
Why?
|
| Cyclooxygenase Inhibitors | 14 | 2017 | 371 | 2.050 |
Why?
|
| Cohort Studies | 131 | 2023 | 40450 | 2.030 |
Why?
|
| Hydroxychloroquine | 13 | 2021 | 408 | 1.980 |
Why?
|
| Arthritis, Psoriatic | 6 | 2019 | 215 | 1.870 |
Why?
|
| Drug Utilization | 11 | 2017 | 1181 | 1.770 |
Why?
|
| Arteritis | 3 | 2024 | 159 | 1.770 |
Why?
|
| Severity of Illness Index | 52 | 2024 | 15530 | 1.720 |
Why?
|
| Analgesics, Opioid | 17 | 2022 | 3667 | 1.710 |
Why?
|
| Withholding Treatment | 8 | 2023 | 598 | 1.700 |
Why?
|
| Lupus Erythematosus, Systemic | 18 | 2023 | 2099 | 1.670 |
Why?
|
| Pennsylvania | 29 | 2011 | 613 | 1.640 |
Why?
|
| Chondrocalcinosis | 6 | 2022 | 79 | 1.640 |
Why?
|
| Risk Factors | 135 | 2024 | 72145 | 1.630 |
Why?
|
| Immunosuppressive Agents | 20 | 2020 | 4147 | 1.610 |
Why?
|
| Spondylarthritis | 6 | 2020 | 62 | 1.490 |
Why?
|
| United States | 153 | 2023 | 69693 | 1.490 |
Why?
|
| Uric Acid | 7 | 2023 | 760 | 1.440 |
Why?
|
| Naproxen | 11 | 2019 | 99 | 1.440 |
Why?
|
| Authorship | 2 | 2023 | 271 | 1.440 |
Why?
|
| Medicare | 45 | 2023 | 6532 | 1.420 |
Why?
|
| Patient Compliance | 11 | 2021 | 2680 | 1.360 |
Why?
|
| Pain | 18 | 2019 | 4961 | 1.320 |
Why?
|
| Antihypertensive Agents | 8 | 2019 | 2043 | 1.310 |
Why?
|
| Hypoglycemic Agents | 9 | 2018 | 2866 | 1.300 |
Why?
|
| Proportional Hazards Models | 49 | 2019 | 12344 | 1.260 |
Why?
|
| Ibuprofen | 9 | 2019 | 235 | 1.250 |
Why?
|
| Aged, 80 and over | 110 | 2023 | 57683 | 1.230 |
Why?
|
| Patient Education as Topic | 13 | 2011 | 2275 | 1.220 |
Why?
|
| Glucocorticoids | 20 | 2019 | 2107 | 1.220 |
Why?
|
| Thiazolidinediones | 5 | 2014 | 476 | 1.220 |
Why?
|
| Publishing | 5 | 2023 | 833 | 1.210 |
Why?
|
| Hip Fractures | 10 | 2017 | 954 | 1.210 |
Why?
|
| Drug Prescriptions | 18 | 2019 | 1636 | 1.200 |
Why?
|
| Psoriasis | 6 | 2017 | 898 | 1.200 |
Why?
|
| Adult | 189 | 2021 | 213712 | 1.180 |
Why?
|
| Diabetes Mellitus | 16 | 2019 | 5724 | 1.160 |
Why?
|
| Comorbidity | 34 | 2023 | 10372 | 1.150 |
Why?
|
| Lactones | 8 | 2019 | 329 | 1.140 |
Why?
|
| Osteoporotic Fractures | 9 | 2019 | 403 | 1.140 |
Why?
|
| Hand Joints | 3 | 2023 | 53 | 1.130 |
Why?
|
| Antibodies, Monoclonal | 17 | 2018 | 9274 | 1.120 |
Why?
|
| Nurse Practitioners | 3 | 2015 | 270 | 1.120 |
Why?
|
| Hyperuricemia | 5 | 2021 | 208 | 1.110 |
Why?
|
| Longitudinal Studies | 32 | 2022 | 13921 | 1.100 |
Why?
|
| Osteoarthritis, Knee | 19 | 2020 | 1222 | 1.100 |
Why?
|
| Incidence | 58 | 2023 | 20928 | 1.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 18 | 2023 | 3239 | 1.070 |
Why?
|
| Myocardial Infarction | 36 | 2022 | 11690 | 1.070 |
Why?
|
| Osteoporosis, Postmenopausal | 6 | 2011 | 386 | 1.070 |
Why?
|
| Databases, Factual | 34 | 2020 | 7716 | 1.060 |
Why?
|
| Arthralgia | 4 | 2020 | 456 | 1.050 |
Why?
|
| Periodicals as Topic | 4 | 2020 | 1431 | 1.040 |
Why?
|
| Editorial Policies | 3 | 2021 | 451 | 1.030 |
Why?
|
| Artificial Intelligence | 3 | 2023 | 2187 | 1.000 |
Why?
|
| Prescription Drugs | 6 | 2021 | 595 | 1.000 |
Why?
|
| Allopurinol | 5 | 2021 | 185 | 0.990 |
Why?
|
| Uterine Cervical Dysplasia | 4 | 2016 | 385 | 0.990 |
Why?
|
| Treatment Outcome | 77 | 2024 | 62966 | 0.970 |
Why?
|
| Pain Measurement | 15 | 2019 | 3418 | 0.940 |
Why?
|
| Drug Substitution | 5 | 2021 | 281 | 0.930 |
Why?
|
| Risk Assessment | 30 | 2020 | 23320 | 0.930 |
Why?
|
| Absorptiometry, Photon | 7 | 2019 | 1726 | 0.930 |
Why?
|
| Comparative Effectiveness Research | 8 | 2020 | 681 | 0.900 |
Why?
|
| Insurance, Pharmaceutical Services | 5 | 2011 | 336 | 0.890 |
Why?
|
| Time Factors | 47 | 2021 | 40054 | 0.880 |
Why?
|
| Metacarpophalangeal Joint | 2 | 2020 | 82 | 0.860 |
Why?
|
| Patient Care Planning | 3 | 2019 | 921 | 0.860 |
Why?
|
| Physician Assistants | 2 | 2015 | 193 | 0.860 |
Why?
|
| Randomized Controlled Trials as Topic | 17 | 2020 | 9941 | 0.840 |
Why?
|
| Metformin | 4 | 2023 | 829 | 0.830 |
Why?
|
| Quality Improvement | 9 | 2021 | 3738 | 0.820 |
Why?
|
| Sulfones | 8 | 2019 | 437 | 0.810 |
Why?
|
| Opportunistic Infections | 5 | 2019 | 389 | 0.810 |
Why?
|
| Polyglutamic Acid | 1 | 2021 | 45 | 0.810 |
Why?
|
| C-Reactive Protein | 14 | 2024 | 3766 | 0.800 |
Why?
|
| Research Design | 19 | 2022 | 5979 | 0.800 |
Why?
|
| Diabetes Mellitus, Type 2 | 9 | 2023 | 11695 | 0.800 |
Why?
|
| Spondylitis, Ankylosing | 2 | 2020 | 155 | 0.790 |
Why?
|
| Education, Distance | 2 | 2022 | 251 | 0.790 |
Why?
|
| Uterine Cervical Neoplasms | 6 | 2016 | 2011 | 0.780 |
Why?
|
| Insurance Claim Review | 8 | 2020 | 720 | 0.780 |
Why?
|
| Antidepressive Agents | 7 | 2019 | 2838 | 0.780 |
Why?
|
| Femur Neck | 7 | 2019 | 309 | 0.780 |
Why?
|
| Remission Induction | 12 | 2019 | 2384 | 0.780 |
Why?
|
| Drug Utilization Review | 7 | 2014 | 245 | 0.770 |
Why?
|
| Propensity Score | 15 | 2021 | 1771 | 0.770 |
Why?
|
| Finger Joint | 2 | 2023 | 108 | 0.760 |
Why?
|
| Disease Management | 6 | 2018 | 2450 | 0.760 |
Why?
|
| Education, Medical, Continuing | 5 | 2009 | 839 | 0.760 |
Why?
|
| Age Factors | 36 | 2020 | 18355 | 0.750 |
Why?
|
| Drug Administration Schedule | 12 | 2020 | 4929 | 0.750 |
Why?
|
| Data Display | 1 | 2021 | 182 | 0.740 |
Why?
|
| Gastrointestinal Diseases | 9 | 2018 | 1167 | 0.740 |
Why?
|
| Rheumatoid Factor | 6 | 2014 | 188 | 0.740 |
Why?
|
| Medical Records | 12 | 2010 | 1413 | 0.730 |
Why?
|
| Retrospective Studies | 72 | 2023 | 77098 | 0.730 |
Why?
|
| Patient Participation | 4 | 2021 | 1445 | 0.730 |
Why?
|
| Probenecid | 2 | 2018 | 74 | 0.710 |
Why?
|
| Medicaid | 15 | 2019 | 2716 | 0.710 |
Why?
|
| Hospitalization | 31 | 2019 | 10232 | 0.710 |
Why?
|
| Plagiarism | 1 | 2019 | 22 | 0.710 |
Why?
|
| Arthroplasty, Replacement, Knee | 12 | 2022 | 1457 | 0.710 |
Why?
|
| Oral Ulcer | 1 | 2020 | 96 | 0.700 |
Why?
|
| Quality Indicators, Health Care | 7 | 2021 | 1831 | 0.700 |
Why?
|
| Double-Blind Method | 16 | 2021 | 12017 | 0.700 |
Why?
|
| Leukopenia | 1 | 2020 | 208 | 0.700 |
Why?
|
| Serologic Tests | 2 | 2017 | 374 | 0.690 |
Why?
|
| Hyperlipidemias | 8 | 2018 | 786 | 0.670 |
Why?
|
| Kidney Diseases | 6 | 2018 | 2145 | 0.670 |
Why?
|
| Depressive Disorder | 4 | 2019 | 3748 | 0.670 |
Why?
|
| Professional Practice | 4 | 2019 | 326 | 0.670 |
Why?
|
| Sulfasalazine | 4 | 2021 | 79 | 0.660 |
Why?
|
| Quality Assurance, Health Care | 9 | 2013 | 2211 | 0.660 |
Why?
|
| Nursing Homes | 8 | 2012 | 1034 | 0.660 |
Why?
|
| Telephone | 4 | 2022 | 617 | 0.650 |
Why?
|
| Quality of Health Care | 13 | 2015 | 4369 | 0.650 |
Why?
|
| New Jersey | 9 | 2011 | 290 | 0.650 |
Why?
|
| Hypertension | 17 | 2023 | 8455 | 0.640 |
Why?
|
| Focus Groups | 4 | 2020 | 1320 | 0.630 |
Why?
|
| Orphan Drug Production | 3 | 2019 | 50 | 0.620 |
Why?
|
| Trust | 3 | 2019 | 501 | 0.620 |
Why?
|
| Biomedical Technology | 1 | 2020 | 221 | 0.620 |
Why?
|
| Jaw Diseases | 2 | 2009 | 90 | 0.620 |
Why?
|
| Patient Care Management | 1 | 2021 | 306 | 0.620 |
Why?
|
| Patient Satisfaction | 10 | 2021 | 3391 | 0.620 |
Why?
|
| Stomatitis | 1 | 2020 | 269 | 0.610 |
Why?
|
| Risk | 25 | 2020 | 9679 | 0.610 |
Why?
|
| Prescriptions | 2 | 2021 | 387 | 0.610 |
Why?
|
| Follow-Up Studies | 36 | 2019 | 39004 | 0.610 |
Why?
|
| Ethics, Research | 1 | 2019 | 190 | 0.610 |
Why?
|
| Chronic Disease | 11 | 2019 | 9144 | 0.600 |
Why?
|
| Logistic Models | 22 | 2019 | 13403 | 0.600 |
Why?
|
| Health Services Accessibility | 7 | 2019 | 5133 | 0.590 |
Why?
|
| Algorithms | 19 | 2023 | 13853 | 0.590 |
Why?
|
| Self Care | 5 | 2013 | 786 | 0.590 |
Why?
|
| Health Care Costs | 12 | 2018 | 3203 | 0.590 |
Why?
|
| Telemedicine | 4 | 2022 | 2853 | 0.590 |
Why?
|
| Sex Factors | 16 | 2020 | 10392 | 0.590 |
Why?
|
| Bone Diseases | 2 | 2012 | 416 | 0.590 |
Why?
|
| Linear Models | 13 | 2020 | 5948 | 0.580 |
Why?
|
| Health Resources | 4 | 2019 | 911 | 0.570 |
Why?
|
| Biological Factors | 2 | 2015 | 164 | 0.570 |
Why?
|
| Neutropenia | 2 | 2020 | 891 | 0.570 |
Why?
|
| Medical Records Systems, Computerized | 5 | 2017 | 1204 | 0.570 |
Why?
|
| International Classification of Diseases | 7 | 2020 | 865 | 0.560 |
Why?
|
| Alopecia | 1 | 2020 | 381 | 0.560 |
Why?
|
| Managed Care Programs | 4 | 2016 | 949 | 0.560 |
Why?
|
| Hand Bones | 1 | 2016 | 13 | 0.560 |
Why?
|
| Guideline Adherence | 7 | 2018 | 2266 | 0.550 |
Why?
|
| Physicians, Family | 5 | 2009 | 345 | 0.550 |
Why?
|
| Drug Approval | 4 | 2016 | 740 | 0.550 |
Why?
|
| Neoplasms | 19 | 2022 | 21596 | 0.550 |
Why?
|
| Stroke | 18 | 2022 | 9963 | 0.550 |
Why?
|
| Receptors, Tumor Necrosis Factor | 6 | 2012 | 595 | 0.550 |
Why?
|
| Health Behavior | 5 | 2016 | 2630 | 0.540 |
Why?
|
| Models, Economic | 6 | 2015 | 713 | 0.540 |
Why?
|
| Osteitis Deformans | 1 | 2015 | 53 | 0.540 |
Why?
|
| Insurance Claim Reporting | 3 | 2007 | 163 | 0.540 |
Why?
|
| Health Status | 6 | 2023 | 4030 | 0.540 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2014 | 3915 | 0.530 |
Why?
|
| Bone Diseases, Metabolic | 2 | 2017 | 417 | 0.530 |
Why?
|
| Fractures, Ununited | 2 | 2008 | 165 | 0.530 |
Why?
|
| Knee Injuries | 7 | 2014 | 490 | 0.530 |
Why?
|
| Peptic Ulcer | 3 | 2009 | 223 | 0.520 |
Why?
|
| Aspirin | 8 | 2018 | 3278 | 0.520 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2021 | 3014 | 0.510 |
Why?
|
| Fibromyalgia | 7 | 2022 | 388 | 0.510 |
Why?
|
| Menstruation | 1 | 2016 | 299 | 0.510 |
Why?
|
| Immunocompromised Host | 5 | 2017 | 847 | 0.510 |
Why?
|
| Xanthine Oxidase | 1 | 2015 | 64 | 0.510 |
Why?
|
| Specialization | 6 | 2015 | 777 | 0.500 |
Why?
|
| Seafood | 1 | 2018 | 384 | 0.500 |
Why?
|
| Gastrointestinal Hemorrhage | 5 | 2017 | 1130 | 0.500 |
Why?
|
| Coronary Vessels | 2 | 2018 | 3099 | 0.490 |
Why?
|
| Physicians' Offices | 1 | 2014 | 58 | 0.490 |
Why?
|
| Patient Selection | 6 | 2017 | 4214 | 0.490 |
Why?
|
| Conflict of Interest | 1 | 2019 | 542 | 0.490 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2017 | 365 | 0.490 |
Why?
|
| Odds Ratio | 16 | 2020 | 9846 | 0.480 |
Why?
|
| United States Food and Drug Administration | 6 | 2016 | 1581 | 0.480 |
Why?
|
| Cyclopropanes | 1 | 2015 | 416 | 0.480 |
Why?
|
| Hepatitis B virus | 1 | 2017 | 513 | 0.480 |
Why?
|
| Familial Mediterranean Fever | 2 | 2015 | 61 | 0.480 |
Why?
|
| Primary Prevention | 2 | 2019 | 1166 | 0.480 |
Why?
|
| Dengue | 1 | 2017 | 256 | 0.480 |
Why?
|
| Databases as Topic | 3 | 2011 | 475 | 0.480 |
Why?
|
| Antidepressive Agents, Tricyclic | 2 | 2013 | 434 | 0.480 |
Why?
|
| Humeral Fractures | 2 | 2008 | 272 | 0.470 |
Why?
|
| Arthrography | 2 | 2011 | 149 | 0.470 |
Why?
|
| Immunoglobulin G | 13 | 2023 | 4554 | 0.470 |
Why?
|
| Autoimmune Diseases | 9 | 2014 | 2130 | 0.470 |
Why?
|
| Histamine H2 Antagonists | 1 | 2015 | 165 | 0.460 |
Why?
|
| Interleukin-1beta | 2 | 2018 | 972 | 0.460 |
Why?
|
| Multivariate Analysis | 21 | 2019 | 12242 | 0.460 |
Why?
|
| Hepatitis B, Chronic | 1 | 2018 | 393 | 0.460 |
Why?
|
| Osteonecrosis | 3 | 2012 | 227 | 0.460 |
Why?
|
| Epidemiologic Methods | 9 | 2017 | 1364 | 0.460 |
Why?
|
| Data Mining | 2 | 2021 | 537 | 0.460 |
Why?
|
| Amitriptyline | 1 | 2013 | 110 | 0.460 |
Why?
|
| Sex Distribution | 11 | 2017 | 2295 | 0.450 |
Why?
|
| Dose-Response Relationship, Drug | 18 | 2021 | 10943 | 0.450 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2017 | 6534 | 0.450 |
Why?
|
| Prunus | 1 | 2012 | 13 | 0.450 |
Why?
|
| Speech Recognition Software | 2 | 2020 | 72 | 0.450 |
Why?
|
| Sulfonamides | 7 | 2015 | 1932 | 0.450 |
Why?
|
| Immunologic Factors | 6 | 2022 | 1575 | 0.450 |
Why?
|
| Atrial Fibrillation | 7 | 2019 | 5019 | 0.440 |
Why?
|
| Folic Acid | 4 | 2021 | 1300 | 0.440 |
Why?
|
| Antibodies, Antinuclear | 4 | 2002 | 326 | 0.440 |
Why?
|
| Coronary Artery Disease | 8 | 2018 | 6454 | 0.440 |
Why?
|
| Proton Pump Inhibitors | 3 | 2015 | 521 | 0.440 |
Why?
|
| Age Distribution | 10 | 2017 | 2900 | 0.440 |
Why?
|
| Osteoarthritis, Hip | 4 | 2020 | 412 | 0.440 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2014 | 297 | 0.440 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2017 | 602 | 0.440 |
Why?
|
| Hypericum | 1 | 2013 | 58 | 0.440 |
Why?
|
| Insect Hormones | 1 | 2012 | 75 | 0.440 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2013 | 143 | 0.440 |
Why?
|
| Cost-Benefit Analysis | 13 | 2016 | 5385 | 0.430 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2012 | 65 | 0.430 |
Why?
|
| Electronic Health Records | 8 | 2023 | 4440 | 0.430 |
Why?
|
| Physician Executives | 1 | 2013 | 128 | 0.430 |
Why?
|
| Insulin | 3 | 2017 | 6575 | 0.430 |
Why?
|
| Insulin Resistance | 4 | 2014 | 3861 | 0.430 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2017 | 2410 | 0.420 |
Why?
|
| Nurse's Role | 1 | 2014 | 209 | 0.420 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2018 | 555 | 0.420 |
Why?
|
| Anemia | 2 | 2020 | 1499 | 0.420 |
Why?
|
| Plant Preparations | 1 | 2013 | 94 | 0.420 |
Why?
|
| Insurance, Health | 7 | 2017 | 2493 | 0.420 |
Why?
|
| Hepatitis B | 1 | 2017 | 695 | 0.420 |
Why?
|
| Calcium Pyrophosphate | 3 | 2022 | 49 | 0.420 |
Why?
|
| Research | 2 | 2020 | 1999 | 0.420 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2015 | 1847 | 0.410 |
Why?
|
| Spinal Fractures | 3 | 2009 | 698 | 0.410 |
Why?
|
| Amines | 1 | 2013 | 278 | 0.410 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 1171 | 0.410 |
Why?
|
| Inflammation | 15 | 2024 | 10578 | 0.410 |
Why?
|
| Pneumococcal Vaccines | 2 | 2013 | 390 | 0.410 |
Why?
|
| Esophageal Neoplasms | 3 | 2011 | 1581 | 0.400 |
Why?
|
| Prospective Studies | 31 | 2020 | 53187 | 0.400 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 1737 | 0.400 |
Why?
|
| Etidronic Acid | 4 | 2009 | 64 | 0.400 |
Why?
|
| Bacterial Infections | 4 | 2019 | 1389 | 0.390 |
Why?
|
| Diaphyses | 1 | 2011 | 65 | 0.390 |
Why?
|
| Drug Therapy, Combination | 14 | 2023 | 6483 | 0.390 |
Why?
|
| Mass Screening | 7 | 2018 | 5238 | 0.390 |
Why?
|
| Femoral Fractures | 2 | 2013 | 376 | 0.380 |
Why?
|
| Lipids | 6 | 2019 | 3302 | 0.380 |
Why?
|
| Pneumococcal Infections | 2 | 2013 | 496 | 0.380 |
Why?
|
| Phytotherapy | 1 | 2013 | 298 | 0.380 |
Why?
|
| Hand | 3 | 2012 | 882 | 0.370 |
Why?
|
| Interleukin-1 | 1 | 2014 | 1262 | 0.370 |
Why?
|
| Administration, Oral | 10 | 2018 | 3913 | 0.370 |
Why?
|
| Narcotics | 3 | 2011 | 343 | 0.370 |
Why?
|
| Pharmacy | 2 | 2022 | 91 | 0.370 |
Why?
|
| Prednisone | 5 | 2015 | 1567 | 0.370 |
Why?
|
| Predictive Value of Tests | 20 | 2017 | 15056 | 0.370 |
Why?
|
| Decision Making | 7 | 2018 | 3869 | 0.370 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2011 | 874 | 0.360 |
Why?
|
| Community Health Centers | 1 | 2013 | 428 | 0.360 |
Why?
|
| Confidence Intervals | 10 | 2018 | 2970 | 0.360 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2014 | 292 | 0.360 |
Why?
|
| Analgesics | 4 | 2017 | 1037 | 0.360 |
Why?
|
| Vasodilation | 1 | 2014 | 944 | 0.360 |
Why?
|
| Information Services | 1 | 2011 | 244 | 0.360 |
Why?
|
| Practice Guidelines as Topic | 12 | 2020 | 7276 | 0.360 |
Why?
|
| Safety-Based Drug Withdrawals | 1 | 2009 | 38 | 0.360 |
Why?
|
| Access to Information | 2 | 2023 | 320 | 0.360 |
Why?
|
| General Practitioners | 1 | 2011 | 103 | 0.350 |
Why?
|
| PPAR gamma | 1 | 2013 | 493 | 0.350 |
Why?
|
| Case-Control Studies | 18 | 2022 | 21719 | 0.350 |
Why?
|
| Calcitonin | 5 | 2010 | 336 | 0.350 |
Why?
|
| Population Surveillance | 1 | 2020 | 2616 | 0.350 |
Why?
|
| Physicians | 5 | 2015 | 4554 | 0.350 |
Why?
|
| Motivation | 2 | 2010 | 1968 | 0.350 |
Why?
|
| Data Collection | 8 | 2013 | 3339 | 0.350 |
Why?
|
| Automobile Driving | 1 | 2014 | 431 | 0.340 |
Why?
|
| Delphi Technique | 2 | 2019 | 778 | 0.340 |
Why?
|
| Prevalence | 19 | 2020 | 15194 | 0.340 |
Why?
|
| Patents as Topic | 1 | 2010 | 103 | 0.340 |
Why?
|
| Metacarpal Bones | 1 | 2009 | 73 | 0.340 |
Why?
|
| Academic Medical Centers | 7 | 2019 | 2749 | 0.340 |
Why?
|
| Angina, Unstable | 3 | 2003 | 926 | 0.330 |
Why?
|
| Thiophenes | 1 | 2013 | 590 | 0.330 |
Why?
|
| Lumbar Vertebrae | 5 | 2017 | 1844 | 0.330 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2010 | 1873 | 0.330 |
Why?
|
| Pneumonia | 2 | 2020 | 2117 | 0.330 |
Why?
|
| Venous Thromboembolism | 3 | 2021 | 1668 | 0.330 |
Why?
|
| Referral and Consultation | 8 | 2022 | 3527 | 0.330 |
Why?
|
| Decision Support Techniques | 3 | 2010 | 1952 | 0.320 |
Why?
|
| Knee Joint | 6 | 2020 | 1679 | 0.320 |
Why?
|
| Quality-Adjusted Life Years | 6 | 2015 | 1679 | 0.320 |
Why?
|
| Histamine Antagonists | 1 | 2008 | 93 | 0.320 |
Why?
|
| Leucovorin | 2 | 2020 | 624 | 0.320 |
Why?
|
| Delivery of Health Care | 4 | 2014 | 5304 | 0.320 |
Why?
|
| Smoking | 9 | 2023 | 8969 | 0.320 |
Why?
|
| Lupus Nephritis | 4 | 2013 | 310 | 0.320 |
Why?
|
| Azathioprine | 3 | 2019 | 355 | 0.320 |
Why?
|
| Alendronate | 3 | 2009 | 171 | 0.320 |
Why?
|
| Quality of Life | 9 | 2019 | 12730 | 0.320 |
Why?
|
| Coronary Circulation | 1 | 2014 | 1572 | 0.320 |
Why?
|
| Fractures, Spontaneous | 3 | 2005 | 230 | 0.320 |
Why?
|
| Graves Disease | 21 | 1985 | 241 | 0.310 |
Why?
|
| Regression Analysis | 9 | 2023 | 6452 | 0.310 |
Why?
|
| Arthroplasty, Replacement, Hip | 5 | 2020 | 1461 | 0.310 |
Why?
|
| Heart Failure | 7 | 2022 | 10856 | 0.310 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 1786 | 0.310 |
Why?
|
| Medicare Part B | 2 | 2012 | 108 | 0.310 |
Why?
|
| Diagnosis-Related Groups | 3 | 2011 | 454 | 0.310 |
Why?
|
| Evidence-Based Medicine | 9 | 2013 | 3611 | 0.310 |
Why?
|
| Chi-Square Distribution | 6 | 2019 | 3510 | 0.300 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 2195 | 0.300 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2013 | 1123 | 0.300 |
Why?
|
| Health Surveys | 7 | 2017 | 4030 | 0.300 |
Why?
|
| Health Care Surveys | 3 | 2014 | 2451 | 0.300 |
Why?
|
| Models, Statistical | 11 | 2022 | 5100 | 0.300 |
Why?
|
| British Columbia | 6 | 2012 | 241 | 0.300 |
Why?
|
| Health Policy | 3 | 2011 | 2657 | 0.300 |
Why?
|
| Jaw | 1 | 2007 | 96 | 0.290 |
Why?
|
| Oligopeptides | 1 | 2012 | 1176 | 0.290 |
Why?
|
| Radiography | 8 | 2023 | 7010 | 0.290 |
Why?
|
| Triiodothyronine | 25 | 1993 | 494 | 0.290 |
Why?
|
| Attitude to Health | 1 | 2016 | 2051 | 0.290 |
Why?
|
| Database Management Systems | 1 | 2008 | 270 | 0.290 |
Why?
|
| Licensure, Medical | 1 | 2007 | 62 | 0.290 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 2007 | 92 | 0.290 |
Why?
|
| Interviews as Topic | 3 | 2014 | 2536 | 0.290 |
Why?
|
| Cross-Sectional Studies | 17 | 2022 | 24913 | 0.290 |
Why?
|
| Physical Examination | 3 | 2004 | 1239 | 0.290 |
Why?
|
| Physicians, Primary Care | 2 | 2019 | 577 | 0.280 |
Why?
|
| Vertebroplasty | 1 | 2007 | 77 | 0.280 |
Why?
|
| Exercise | 1 | 2023 | 5611 | 0.280 |
Why?
|
| Body Mass Index | 11 | 2022 | 12695 | 0.280 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2012 | 469 | 0.280 |
Why?
|
| Educational Status | 3 | 2023 | 2533 | 0.280 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2011 | 941 | 0.280 |
Why?
|
| Lipoproteins, HDL | 2 | 2012 | 637 | 0.280 |
Why?
|
| Mycophenolic Acid | 2 | 2019 | 343 | 0.280 |
Why?
|
| Prognosis | 16 | 2022 | 29010 | 0.280 |
Why?
|
| Healthcare Disparities | 4 | 2017 | 3151 | 0.270 |
Why?
|
| Hip Joint | 4 | 2017 | 1002 | 0.270 |
Why?
|
| Reproducibility of Results | 14 | 2021 | 19862 | 0.270 |
Why?
|
| Insurance Benefits | 2 | 2019 | 183 | 0.270 |
Why?
|
| Disability Evaluation | 5 | 2023 | 1827 | 0.270 |
Why?
|
| Pharmaceutical Services | 2 | 2018 | 140 | 0.270 |
Why?
|
| Patient Care | 2 | 2014 | 639 | 0.270 |
Why?
|
| Tramadol | 3 | 2016 | 50 | 0.270 |
Why?
|
| Sensitivity and Specificity | 20 | 2020 | 14720 | 0.270 |
Why?
|
| Eating | 1 | 2012 | 1535 | 0.270 |
Why?
|
| Documentation | 3 | 2007 | 865 | 0.270 |
Why?
|
| Menisci, Tibial | 3 | 2020 | 269 | 0.260 |
Why?
|
| Low Back Pain | 2 | 2022 | 955 | 0.260 |
Why?
|
| Recurrence | 5 | 2019 | 8333 | 0.260 |
Why?
|
| Virus Diseases | 2 | 2019 | 710 | 0.260 |
Why?
|
| Immunologic Tests | 2 | 2003 | 103 | 0.260 |
Why?
|
| Feeding Behavior | 1 | 2017 | 3187 | 0.260 |
Why?
|
| Public Opinion | 2 | 2006 | 477 | 0.260 |
Why?
|
| Drug and Narcotic Control | 1 | 2006 | 146 | 0.250 |
Why?
|
| Morbidity | 4 | 2020 | 1767 | 0.250 |
Why?
|
| Pharmacies | 2 | 2021 | 150 | 0.250 |
Why?
|
| Isoenzymes | 3 | 2004 | 1725 | 0.250 |
Why?
|
| Disease Progression | 12 | 2019 | 13256 | 0.250 |
Why?
|
| Teaching Materials | 1 | 2005 | 86 | 0.250 |
Why?
|
| Inflammation Mediators | 3 | 2019 | 1889 | 0.250 |
Why?
|
| Hypolipidemic Agents | 6 | 2018 | 604 | 0.250 |
Why?
|
| Natural Language Processing | 3 | 2023 | 1035 | 0.250 |
Why?
|
| Peer Review, Research | 2 | 2019 | 329 | 0.240 |
Why?
|
| Shoulder Pain | 3 | 2001 | 145 | 0.240 |
Why?
|
| Positron-Emission Tomography | 2 | 2018 | 6259 | 0.240 |
Why?
|
| Necrosis | 2 | 2022 | 1643 | 0.240 |
Why?
|
| Cross-Over Studies | 4 | 2015 | 2030 | 0.240 |
Why?
|
| Musculoskeletal Diseases | 3 | 2001 | 581 | 0.240 |
Why?
|
| Point-of-Care Systems | 1 | 2013 | 1175 | 0.240 |
Why?
|
| Primary Health Care | 5 | 2016 | 4551 | 0.240 |
Why?
|
| Massachusetts | 6 | 2020 | 8662 | 0.230 |
Why?
|
| Epidemiologic Studies | 2 | 2006 | 676 | 0.230 |
Why?
|
| Diet Surveys | 2 | 2018 | 1172 | 0.230 |
Why?
|
| Cluster Analysis | 6 | 2020 | 2713 | 0.230 |
Why?
|
| Nutrition Surveys | 3 | 2018 | 1656 | 0.230 |
Why?
|
| Tuberculosis, Osteoarticular | 1 | 2003 | 26 | 0.230 |
Why?
|
| Medication Systems, Hospital | 2 | 2020 | 158 | 0.230 |
Why?
|
| Joint Diseases | 3 | 2004 | 478 | 0.220 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2021 | 65 | 0.220 |
Why?
|
| Diabetes Complications | 2 | 2008 | 1359 | 0.220 |
Why?
|
| Glomerular Filtration Rate | 4 | 2021 | 2167 | 0.220 |
Why?
|
| Coronary Disease | 4 | 2019 | 6078 | 0.220 |
Why?
|
| Drug Costs | 6 | 2015 | 1104 | 0.220 |
Why?
|
| Poverty | 3 | 2014 | 2646 | 0.220 |
Why?
|
| Family Practice | 2 | 2003 | 516 | 0.220 |
Why?
|
| Obesity | 7 | 2017 | 12705 | 0.220 |
Why?
|
| Cost of Illness | 4 | 2019 | 1852 | 0.210 |
Why?
|
| Adolescent | 34 | 2020 | 85649 | 0.210 |
Why?
|
| Oxycodone | 2 | 2016 | 152 | 0.210 |
Why?
|
| Cholesterol, LDL | 3 | 2016 | 2354 | 0.210 |
Why?
|
| Data Interpretation, Statistical | 7 | 2018 | 2714 | 0.210 |
Why?
|
| Blood Pressure | 5 | 2019 | 8541 | 0.210 |
Why?
|
| Coronary Artery Bypass | 5 | 2015 | 2281 | 0.210 |
Why?
|
| Hormone Replacement Therapy | 2 | 2015 | 744 | 0.210 |
Why?
|
| Science | 1 | 2005 | 241 | 0.210 |
Why?
|
| Preventive Health Services | 1 | 2007 | 575 | 0.210 |
Why?
|
| Program Development | 1 | 2008 | 1314 | 0.200 |
Why?
|
| Drug Discovery | 1 | 2010 | 1057 | 0.200 |
Why?
|
| International Cooperation | 1 | 2008 | 1421 | 0.200 |
Why?
|
| Heart Diseases | 2 | 2015 | 2789 | 0.200 |
Why?
|
| Pain Threshold | 3 | 2015 | 585 | 0.200 |
Why?
|
| Accidental Falls | 3 | 2019 | 1057 | 0.200 |
Why?
|
| Socioeconomic Factors | 7 | 2019 | 7770 | 0.200 |
Why?
|
| Thyroxine | 25 | 1993 | 666 | 0.200 |
Why?
|
| Knee | 1 | 2003 | 274 | 0.200 |
Why?
|
| Thoracic Vertebrae | 1 | 2006 | 604 | 0.200 |
Why?
|
| Motor Activity | 2 | 2015 | 2714 | 0.200 |
Why?
|
| Suicide | 2 | 2010 | 1475 | 0.200 |
Why?
|
| Fluorobenzenes | 2 | 2015 | 184 | 0.190 |
Why?
|
| Long-Acting Thyroid Stimulator | 13 | 1979 | 13 | 0.190 |
Why?
|
| Sulfonylurea Compounds | 2 | 2014 | 204 | 0.190 |
Why?
|
| Colonic Neoplasms | 1 | 2012 | 2542 | 0.190 |
Why?
|
| Postmenopause | 4 | 2016 | 2461 | 0.190 |
Why?
|
| Young Adult | 23 | 2020 | 56350 | 0.190 |
Why?
|
| Reimbursement Mechanisms | 1 | 2006 | 670 | 0.180 |
Why?
|
| Menopause | 3 | 2019 | 1621 | 0.180 |
Why?
|
| Self Efficacy | 3 | 2011 | 610 | 0.180 |
Why?
|
| Cholesterol | 2 | 2007 | 2895 | 0.180 |
Why?
|
| Physician-Patient Relations | 7 | 2021 | 3215 | 0.180 |
Why?
|
| Triangular Fibrocartilage | 1 | 2020 | 28 | 0.180 |
Why?
|
| Treatment Failure | 4 | 2013 | 2615 | 0.180 |
Why?
|
| Thyronines | 7 | 1988 | 7 | 0.180 |
Why?
|
| Taiwan | 2 | 2017 | 496 | 0.180 |
Why?
|
| Benzodiazepines | 1 | 2005 | 1101 | 0.180 |
Why?
|
| Office Visits | 4 | 2013 | 598 | 0.170 |
Why?
|
| Computer Simulation | 8 | 2019 | 6191 | 0.170 |
Why?
|
| Patients | 1 | 2006 | 892 | 0.170 |
Why?
|
| Diagnostic Tests, Routine | 3 | 2012 | 783 | 0.170 |
Why?
|
| Thyroid Gland | 21 | 1979 | 1172 | 0.170 |
Why?
|
| Diet | 1 | 2017 | 7923 | 0.170 |
Why?
|
| User-Computer Interface | 1 | 2006 | 1426 | 0.170 |
Why?
|
| Perimenopause | 1 | 2020 | 139 | 0.170 |
Why?
|
| Terminology as Topic | 4 | 2013 | 1548 | 0.170 |
Why?
|
| Treatment Refusal | 3 | 2007 | 416 | 0.170 |
Why?
|
| Nurses | 3 | 2014 | 2459 | 0.170 |
Why?
|
| Pancytopenia | 1 | 2020 | 104 | 0.170 |
Why?
|
| Self Report | 6 | 2020 | 3548 | 0.170 |
Why?
|
| Osteomyelitis | 1 | 2003 | 402 | 0.170 |
Why?
|
| Interleukin-18 | 1 | 2020 | 248 | 0.170 |
Why?
|
| Ligaments, Articular | 1 | 2001 | 298 | 0.170 |
Why?
|
| Knee Prosthesis | 2 | 2013 | 425 | 0.170 |
Why?
|
| HIV Infections | 3 | 2016 | 16678 | 0.160 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2015 | 1239 | 0.160 |
Why?
|
| Cardiotonic Agents | 1 | 2002 | 535 | 0.160 |
Why?
|
| Aging | 2 | 2016 | 8626 | 0.160 |
Why?
|
| Autoantibodies | 9 | 2014 | 2036 | 0.160 |
Why?
|
| Uricosuric Agents | 1 | 2018 | 26 | 0.160 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 3070 | 0.160 |
Why?
|
| Hepatitis B Antigens | 1 | 2017 | 40 | 0.160 |
Why?
|
| Hip | 1 | 2019 | 257 | 0.160 |
Why?
|
| Drug Monitoring | 2 | 2019 | 956 | 0.160 |
Why?
|
| Simvastatin | 2 | 2012 | 360 | 0.160 |
Why?
|
| Activities of Daily Living | 3 | 2005 | 2414 | 0.160 |
Why?
|
| Republic of Korea | 2 | 2019 | 538 | 0.160 |
Why?
|
| Spine | 2 | 2019 | 1143 | 0.160 |
Why?
|
| Canada | 3 | 2012 | 2061 | 0.160 |
Why?
|
| Gastrointestinal Agents | 1 | 2003 | 494 | 0.160 |
Why?
|
| Patient Discharge | 6 | 2014 | 3300 | 0.160 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2013 | 1788 | 0.150 |
Why?
|
| Cardiovascular System | 1 | 2005 | 827 | 0.150 |
Why?
|
| Vitamin B Complex | 1 | 2020 | 288 | 0.150 |
Why?
|
| Kidney | 4 | 2021 | 7167 | 0.150 |
Why?
|
| Maryland | 1 | 2018 | 276 | 0.150 |
Why?
|
| Hepatitis B Antibodies | 1 | 2017 | 159 | 0.150 |
Why?
|
| Epidemiologic Research Design | 2 | 2013 | 367 | 0.150 |
Why?
|
| Placebos | 2 | 2020 | 1677 | 0.150 |
Why?
|
| Boston | 4 | 2017 | 9305 | 0.150 |
Why?
|
| Drug Labeling | 2 | 2009 | 231 | 0.150 |
Why?
|
| Injections | 1 | 2020 | 840 | 0.150 |
Why?
|
| Pregnancy Complications | 1 | 2011 | 2861 | 0.150 |
Why?
|
| Range of Motion, Articular | 2 | 2019 | 1577 | 0.140 |
Why?
|
| Single-Blind Method | 2 | 2012 | 1589 | 0.140 |
Why?
|
| Myocardial Revascularization | 2 | 2013 | 841 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 3 | 2015 | 7153 | 0.140 |
Why?
|
| Residence Characteristics | 4 | 2019 | 2049 | 0.140 |
Why?
|
| Ulna | 1 | 2017 | 133 | 0.140 |
Why?
|
| Lipoproteins, LDL | 2 | 2012 | 628 | 0.140 |
Why?
|
| Pyrazoles | 5 | 2009 | 1970 | 0.140 |
Why?
|
| Medical History Taking | 1 | 2000 | 783 | 0.140 |
Why?
|
| Kidney Failure, Chronic | 4 | 2011 | 2536 | 0.140 |
Why?
|
| Fatigue | 3 | 2022 | 1526 | 0.140 |
Why?
|
| Unnecessary Procedures | 1 | 1999 | 431 | 0.140 |
Why?
|
| Medication Therapy Management | 1 | 2017 | 127 | 0.130 |
Why?
|
| Bone Remodeling | 1 | 2019 | 575 | 0.130 |
Why?
|
| Anticonvulsants | 1 | 2005 | 1914 | 0.130 |
Why?
|
| Vulnerable Populations | 2 | 2019 | 685 | 0.130 |
Why?
|
| Stomach Diseases | 1 | 1997 | 134 | 0.130 |
Why?
|
| Cooking | 1 | 2018 | 312 | 0.130 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2015 | 76 | 0.130 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 1999 | 300 | 0.130 |
Why?
|
| Receptors, Histamine H2 | 1 | 2015 | 18 | 0.130 |
Why?
|
| Myocardial Ischemia | 2 | 2022 | 2145 | 0.130 |
Why?
|
| Drug Interactions | 2 | 2015 | 1458 | 0.130 |
Why?
|
| TNF Receptor-Associated Factor 1 | 1 | 2015 | 50 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2020 | 20086 | 0.130 |
Why?
|
| Estrogen Replacement Therapy | 4 | 2011 | 1202 | 0.130 |
Why?
|
| Intention to Treat Analysis | 4 | 2018 | 425 | 0.130 |
Why?
|
| Medical Audit | 3 | 2008 | 467 | 0.130 |
Why?
|
| Sleep | 2 | 2021 | 4604 | 0.130 |
Why?
|
| Nutritive Value | 1 | 2018 | 339 | 0.130 |
Why?
|
| Clarithromycin | 1 | 2015 | 86 | 0.130 |
Why?
|
| Vaccination | 1 | 2007 | 3256 | 0.130 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 1342 | 0.130 |
Why?
|
| Qualitative Research | 4 | 2021 | 2680 | 0.130 |
Why?
|
| Minority Groups | 2 | 2013 | 1215 | 0.120 |
Why?
|
| Peptides, Cyclic | 3 | 2012 | 401 | 0.120 |
Why?
|
| Reminder Systems | 2 | 2011 | 370 | 0.120 |
Why?
|
| Japan | 2 | 2015 | 1360 | 0.120 |
Why?
|
| Thyrotropin | 20 | 1993 | 850 | 0.120 |
Why?
|
| Utilization Review | 5 | 2003 | 392 | 0.120 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1999 | 719 | 0.120 |
Why?
|
| Wrist Injuries | 1 | 2017 | 208 | 0.120 |
Why?
|
| Anti-Ulcer Agents | 2 | 2018 | 119 | 0.120 |
Why?
|
| Leptin | 2 | 2012 | 1593 | 0.120 |
Why?
|
| Regional Blood Flow | 1 | 2018 | 1525 | 0.120 |
Why?
|
| Radius | 1 | 2017 | 422 | 0.120 |
Why?
|
| Medical Record Linkage | 1 | 2015 | 284 | 0.120 |
Why?
|
| Cyclophosphamide | 2 | 2017 | 2236 | 0.120 |
Why?
|
| Physician's Role | 3 | 2011 | 942 | 0.120 |
Why?
|
| Hematinics | 1 | 2017 | 281 | 0.120 |
Why?
|
| Blood Glucose | 2 | 2023 | 6249 | 0.120 |
Why?
|
| Measles | 1 | 2015 | 168 | 0.120 |
Why?
|
| Aortitis | 1 | 2014 | 73 | 0.120 |
Why?
|
| Health Services Research | 4 | 2015 | 1834 | 0.120 |
Why?
|
| Calcinosis | 1 | 2022 | 1497 | 0.120 |
Why?
|
| Research Report | 1 | 2016 | 355 | 0.110 |
Why?
|
| Imidazoles | 2 | 2017 | 1205 | 0.110 |
Why?
|
| Radioimmunoassay | 13 | 1993 | 918 | 0.110 |
Why?
|
| Endarterectomy | 2 | 1990 | 195 | 0.110 |
Why?
|
| Polypharmacy | 2 | 2006 | 294 | 0.110 |
Why?
|
| Biomedical Research | 4 | 2017 | 3306 | 0.110 |
Why?
|
| Rheumatic Fever | 1 | 2013 | 71 | 0.110 |
Why?
|
| Brazil | 1 | 2017 | 1263 | 0.110 |
Why?
|
| Vaginal Smears | 2 | 2014 | 511 | 0.110 |
Why?
|
| Critical Pathways | 2 | 2010 | 475 | 0.110 |
Why?
|
| Economic Competition | 1 | 2015 | 214 | 0.110 |
Why?
|
| Carbonated Beverages | 1 | 2014 | 214 | 0.110 |
Why?
|
| Waiting Lists | 1 | 2017 | 692 | 0.110 |
Why?
|
| Remote Consultation | 2 | 2020 | 238 | 0.110 |
Why?
|
| Thyroid Hormones | 6 | 1987 | 390 | 0.110 |
Why?
|
| Densitometry | 2 | 2004 | 156 | 0.110 |
Why?
|
| Cyclohexanols | 1 | 2013 | 127 | 0.110 |
Why?
|
| Cause of Death | 4 | 2018 | 3571 | 0.110 |
Why?
|
| Thyroid Function Tests | 7 | 1987 | 284 | 0.110 |
Why?
|
| Dietary Sucrose | 1 | 2014 | 247 | 0.110 |
Why?
|
| Counseling | 2 | 2011 | 1521 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 2 | 2007 | 1661 | 0.100 |
Why?
|
| Ipodate | 4 | 1985 | 8 | 0.100 |
Why?
|
| North America | 1 | 2015 | 1249 | 0.100 |
Why?
|
| Resistin | 1 | 2012 | 170 | 0.100 |
Why?
|
| Hyperthyroidism | 13 | 1988 | 293 | 0.100 |
Why?
|
| Atherosclerosis | 3 | 2018 | 3428 | 0.100 |
Why?
|
| Microsomes | 6 | 1992 | 257 | 0.100 |
Why?
|
| Frail Elderly | 2 | 2010 | 691 | 0.100 |
Why?
|
| Synovial Membrane | 1 | 2014 | 506 | 0.100 |
Why?
|
| Sertraline | 1 | 2013 | 206 | 0.100 |
Why?
|
| Early Diagnosis | 2 | 2018 | 1184 | 0.100 |
Why?
|
| Azetidines | 1 | 2012 | 142 | 0.100 |
Why?
|
| Drug Industry | 2 | 2010 | 744 | 0.100 |
Why?
|
| Lipoproteins | 2 | 2013 | 876 | 0.100 |
Why?
|
| Arthroscopy | 2 | 2012 | 924 | 0.100 |
Why?
|
| Patient Preference | 1 | 2018 | 886 | 0.100 |
Why?
|
| Goals | 1 | 2016 | 705 | 0.100 |
Why?
|
| Dextropropoxyphene | 1 | 2010 | 26 | 0.100 |
Why?
|
| Information Storage and Retrieval | 1 | 2017 | 824 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2022 | 5975 | 0.100 |
Why?
|
| Coronary Angiography | 5 | 2007 | 4567 | 0.100 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2015 | 1517 | 0.100 |
Why?
|
| Anti-Anxiety Agents | 1 | 2013 | 390 | 0.100 |
Why?
|
| Postoperative Complications | 6 | 2019 | 15244 | 0.100 |
Why?
|
| Codeine | 1 | 2010 | 49 | 0.100 |
Why?
|
| DNA, Viral | 1 | 2017 | 2224 | 0.100 |
Why?
|
| Hydrocodone | 1 | 2010 | 46 | 0.100 |
Why?
|
| Streptococcus pyogenes | 1 | 2013 | 289 | 0.100 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2012 | 135 | 0.100 |
Why?
|
| Pyrimidines | 2 | 2015 | 2933 | 0.100 |
Why?
|
| Forecasting | 4 | 2008 | 2948 | 0.090 |
Why?
|
| Alcohol Drinking | 3 | 2014 | 3957 | 0.090 |
Why?
|
| Pain, Intractable | 1 | 2011 | 130 | 0.090 |
Why?
|
| Herpes Zoster | 1 | 2013 | 264 | 0.090 |
Why?
|
| Optic Neuritis | 1 | 2012 | 166 | 0.090 |
Why?
|
| Off-Label Use | 1 | 2012 | 169 | 0.090 |
Why?
|
| Ultrasonography | 2 | 2021 | 5978 | 0.090 |
Why?
|
| Immune System Diseases | 1 | 2013 | 262 | 0.090 |
Why?
|
| Arthritis, Gouty | 1 | 2010 | 28 | 0.090 |
Why?
|
| Thyroxine-Binding Proteins | 4 | 1986 | 24 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2019 | 2245 | 0.090 |
Why?
|
| Steroids | 1 | 2015 | 931 | 0.090 |
Why?
|
| Drug Recalls | 1 | 2009 | 17 | 0.090 |
Why?
|
| Veterans | 2 | 2022 | 2513 | 0.090 |
Why?
|
| Fibrinolytic Agents | 3 | 2010 | 2156 | 0.090 |
Why?
|
| Random Allocation | 3 | 2004 | 2425 | 0.090 |
Why?
|
| Cooperative Behavior | 1 | 2017 | 1503 | 0.090 |
Why?
|
| Analysis of Variance | 4 | 2017 | 6365 | 0.090 |
Why?
|
| Carotid Stenosis | 2 | 1996 | 854 | 0.090 |
Why?
|
| Joints | 1 | 2011 | 326 | 0.090 |
Why?
|
| Device Approval | 1 | 2011 | 163 | 0.090 |
Why?
|
| Survival Rate | 4 | 2020 | 12773 | 0.090 |
Why?
|
| Consensus | 1 | 2019 | 2935 | 0.090 |
Why?
|
| Wrist Joint | 2 | 2023 | 256 | 0.090 |
Why?
|
| Prosthesis Failure | 2 | 2013 | 1203 | 0.090 |
Why?
|
| Drug Therapy | 3 | 2012 | 497 | 0.090 |
Why?
|
| Mental Disorders | 2 | 2012 | 6587 | 0.090 |
Why?
|
| Australia | 1 | 2013 | 1167 | 0.090 |
Why?
|
| Renal Replacement Therapy | 1 | 2011 | 258 | 0.090 |
Why?
|
| Demography | 1 | 2014 | 1650 | 0.090 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2010 | 349 | 0.090 |
Why?
|
| Markov Chains | 1 | 2013 | 969 | 0.090 |
Why?
|
| Reference Values | 3 | 2015 | 4982 | 0.090 |
Why?
|
| Carotid Arteries | 2 | 1990 | 952 | 0.090 |
Why?
|
| Blood Proteins | 3 | 1987 | 1122 | 0.090 |
Why?
|
| Physical Therapy Modalities | 1 | 2013 | 547 | 0.080 |
Why?
|
| Community Pharmacy Services | 1 | 2009 | 46 | 0.080 |
Why?
|
| Acute Coronary Syndrome | 1 | 2022 | 2337 | 0.080 |
Why?
|
| Mammography | 2 | 2012 | 2474 | 0.080 |
Why?
|
| Hydrochlorothiazide | 1 | 2009 | 98 | 0.080 |
Why?
|
| Pulmonary Embolism | 1 | 2021 | 2370 | 0.080 |
Why?
|
| Mandible | 1 | 2013 | 740 | 0.080 |
Why?
|
| Probability | 3 | 2022 | 2502 | 0.080 |
Why?
|
| Depression | 2 | 2019 | 7733 | 0.080 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 1813 | 0.080 |
Why?
|
| Medicine | 5 | 2009 | 941 | 0.080 |
Why?
|
| Hospital Bed Capacity | 1 | 2009 | 213 | 0.080 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2010 | 230 | 0.080 |
Why?
|
| Sulfinpyrazone | 1 | 2007 | 13 | 0.080 |
Why?
|
| Epidemiologic Factors | 1 | 2007 | 30 | 0.080 |
Why?
|
| Legislation, Drug | 1 | 2010 | 206 | 0.080 |
Why?
|
| Hospitals | 7 | 2010 | 3937 | 0.080 |
Why?
|
| Virus Activation | 1 | 2010 | 319 | 0.080 |
Why?
|
| Health Services | 3 | 2012 | 758 | 0.080 |
Why?
|
| Phenotype | 3 | 2015 | 16331 | 0.080 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2010 | 332 | 0.080 |
Why?
|
| HLA-DR4 Antigen | 1 | 2007 | 28 | 0.080 |
Why?
|
| Community Health Services | 2 | 2012 | 650 | 0.080 |
Why?
|
| Dyslipidemias | 1 | 2015 | 848 | 0.080 |
Why?
|
| Learning | 1 | 2017 | 1705 | 0.080 |
Why?
|
| Management Information Systems | 1 | 2007 | 50 | 0.080 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 802 | 0.080 |
Why?
|
| American Medical Association | 1 | 2007 | 65 | 0.080 |
Why?
|
| Efficiency, Organizational | 1 | 2012 | 695 | 0.080 |
Why?
|
| Body Weight | 3 | 2017 | 4664 | 0.070 |
Why?
|
| Biological Assay | 8 | 2021 | 652 | 0.070 |
Why?
|
| Population | 1 | 2007 | 142 | 0.070 |
Why?
|
| Placebo Effect | 1 | 2011 | 502 | 0.070 |
Why?
|
| Fractures, Compression | 1 | 2009 | 134 | 0.070 |
Why?
|
| Home Care Services | 1 | 1993 | 602 | 0.070 |
Why?
|
| England | 1 | 2008 | 523 | 0.070 |
Why?
|
| Analgesia | 1 | 2011 | 459 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2018 | 8297 | 0.070 |
Why?
|
| Acute Disease | 6 | 2020 | 7141 | 0.070 |
Why?
|
| Aorta | 1 | 2014 | 2057 | 0.070 |
Why?
|
| Occult Blood | 1 | 2007 | 176 | 0.070 |
Why?
|
| Prescription Fees | 1 | 2007 | 146 | 0.070 |
Why?
|
| Immunoconjugates | 1 | 2013 | 897 | 0.070 |
Why?
|
| Antithyroid Agents | 2 | 1985 | 68 | 0.070 |
Why?
|
| Medical Staff, Hospital | 2 | 2001 | 603 | 0.070 |
Why?
|
| Humerus | 2 | 2010 | 265 | 0.070 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2004 | 329 | 0.070 |
Why?
|
| Radius Fractures | 2 | 2010 | 499 | 0.070 |
Why?
|
| Health Educators | 1 | 2005 | 20 | 0.070 |
Why?
|
| Interleukin-6 | 2 | 2018 | 3199 | 0.070 |
Why?
|
| Prejudice | 1 | 2010 | 569 | 0.070 |
Why?
|
| Abortion, Spontaneous | 1 | 2011 | 542 | 0.070 |
Why?
|
| Diiodothyronines | 3 | 1979 | 5 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 2013 | 0.070 |
Why?
|
| Clinical Trials as Topic | 3 | 2012 | 7901 | 0.070 |
Why?
|
| Antiviral Agents | 1 | 2018 | 2978 | 0.070 |
Why?
|
| Professional-Patient Relations | 1 | 2011 | 736 | 0.070 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 2699 | 0.070 |
Why?
|
| Medical Assistance | 1 | 2005 | 104 | 0.070 |
Why?
|
| Biopsy | 1 | 2017 | 6756 | 0.060 |
Why?
|
| Vitamin D | 1 | 2019 | 3211 | 0.060 |
Why?
|
| Ofloxacin | 2 | 2003 | 65 | 0.060 |
Why?
|
| Technology Assessment, Biomedical | 2 | 2003 | 307 | 0.060 |
Why?
|
| Longevity | 1 | 2013 | 1069 | 0.060 |
Why?
|
| Administration, Inhalation | 1 | 2008 | 1104 | 0.060 |
Why?
|
| Income | 1 | 2014 | 1904 | 0.060 |
Why?
|
| Cost Savings | 1 | 2010 | 925 | 0.060 |
Why?
|
| Clinical Competence | 3 | 2009 | 4681 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 20774 | 0.060 |
Why?
|
| Life Expectancy | 1 | 2011 | 1183 | 0.060 |
Why?
|
| Bacterial Vaccines | 1 | 2007 | 402 | 0.060 |
Why?
|
| Hemoglobins | 1 | 2010 | 1532 | 0.060 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2013 | 807 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 2 | 2004 | 611 | 0.060 |
Why?
|
| Formularies as Topic | 1 | 2004 | 91 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 2658 | 0.060 |
Why?
|
| Health Education | 1 | 2011 | 1053 | 0.060 |
Why?
|
| Allied Health Personnel | 1 | 2005 | 162 | 0.060 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 1123 | 0.060 |
Why?
|
| Hospitals, Veterans | 1 | 2006 | 404 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2015 | 2527 | 0.060 |
Why?
|
| Consumer Product Safety | 1 | 2005 | 122 | 0.060 |
Why?
|
| Hospital Records | 1 | 2004 | 95 | 0.060 |
Why?
|
| Sample Size | 1 | 2007 | 844 | 0.060 |
Why?
|
| Shoulder Joint | 2 | 2001 | 693 | 0.060 |
Why?
|
| Drugs, Generic | 1 | 2009 | 422 | 0.060 |
Why?
|
| SEER Program | 1 | 2009 | 1507 | 0.060 |
Why?
|
| Length of Stay | 4 | 2010 | 6294 | 0.060 |
Why?
|
| Anti-Retroviral Agents | 1 | 2013 | 1712 | 0.060 |
Why?
|
| Cost Control | 1 | 2006 | 624 | 0.060 |
Why?
|
| Skin | 1 | 2017 | 4353 | 0.060 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2006 | 392 | 0.060 |
Why?
|
| Pharmacogenetics | 1 | 2008 | 676 | 0.060 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2004 | 214 | 0.060 |
Why?
|
| Surgical Procedures, Operative | 2 | 2005 | 1873 | 0.060 |
Why?
|
| Polysaccharides | 1 | 2010 | 1051 | 0.060 |
Why?
|
| Geriatrics | 1 | 1988 | 396 | 0.060 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 1985 | 402 | 0.060 |
Why?
|
| Creatinine | 2 | 2007 | 1916 | 0.060 |
Why?
|
| Pre-Eclampsia | 1 | 2012 | 1196 | 0.060 |
Why?
|
| Endpoint Determination | 1 | 2006 | 600 | 0.060 |
Why?
|
| Medication Errors | 1 | 2009 | 797 | 0.060 |
Why?
|
| Heparin | 1 | 2010 | 1636 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2010 | 6891 | 0.050 |
Why?
|
| Ambulatory Care | 2 | 2013 | 2706 | 0.050 |
Why?
|
| Diagnostic Errors | 2 | 2009 | 1255 | 0.050 |
Why?
|
| Internet | 2 | 2012 | 3062 | 0.050 |
Why?
|
| Creatine Kinase | 1 | 2004 | 694 | 0.050 |
Why?
|
| Indians, North American | 2 | 2018 | 353 | 0.050 |
Why?
|
| Control Groups | 1 | 2022 | 105 | 0.050 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2003 | 203 | 0.050 |
Why?
|
| Puerto Rico | 1 | 2003 | 356 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2010 | 2739 | 0.050 |
Why?
|
| Radiology Department, Hospital | 1 | 2006 | 412 | 0.050 |
Why?
|
| Reimbursement, Incentive | 1 | 2007 | 540 | 0.050 |
Why?
|
| Suicide, Attempted | 1 | 2010 | 1218 | 0.050 |
Why?
|
| Self-Help Groups | 1 | 2003 | 187 | 0.050 |
Why?
|
| Hypothyroidism | 9 | 1988 | 659 | 0.050 |
Why?
|
| Pandemics | 1 | 2022 | 8328 | 0.050 |
Why?
|
| Vitamin B 12 | 1 | 2004 | 527 | 0.050 |
Why?
|
| Ceftazidime | 1 | 2001 | 68 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2003 | 35342 | 0.050 |
Why?
|
| Public Health | 2 | 2012 | 2594 | 0.050 |
Why?
|
| Posterior Cruciate Ligament | 1 | 2001 | 88 | 0.050 |
Why?
|
| Genotype | 1 | 2015 | 12946 | 0.050 |
Why?
|
| Shoulder | 1 | 2003 | 299 | 0.050 |
Why?
|
| Incidental Findings | 1 | 2006 | 688 | 0.050 |
Why?
|
| Anti-HIV Agents | 2 | 2016 | 4250 | 0.050 |
Why?
|
| Observer Variation | 1 | 2007 | 2593 | 0.050 |
Why?
|
| Reference Standards | 1 | 2004 | 1020 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2002 | 2505 | 0.050 |
Why?
|
| Medical Records, Problem-Oriented | 1 | 2000 | 35 | 0.050 |
Why?
|
| Cephalosporins | 1 | 2001 | 203 | 0.050 |
Why?
|
| Troponin | 1 | 2004 | 524 | 0.050 |
Why?
|
| Pregnancy | 10 | 2012 | 29087 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2017 | 15494 | 0.050 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2002 | 286 | 0.050 |
Why?
|
| New England | 1 | 2003 | 1021 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2002 | 981 | 0.040 |
Why?
|
| Insurance Carriers | 1 | 2021 | 156 | 0.040 |
Why?
|
| Influenza Vaccines | 1 | 2007 | 733 | 0.040 |
Why?
|
| Thyroid Diseases | 4 | 1999 | 378 | 0.040 |
Why?
|
| Scleroderma, Systemic | 1 | 2003 | 313 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2006 | 1265 | 0.040 |
Why?
|
| Multiple Sclerosis | 1 | 2014 | 3076 | 0.040 |
Why?
|
| Neuralgia | 2 | 2019 | 568 | 0.040 |
Why?
|
| Antibodies | 6 | 2012 | 2459 | 0.040 |
Why?
|
| Child, Preschool | 5 | 2013 | 40955 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2000 | 428 | 0.040 |
Why?
|
| Discriminant Analysis | 1 | 1999 | 235 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 8925 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2018 | 2885 | 0.040 |
Why?
|
| Thyrotropin-Releasing Hormone | 5 | 1977 | 147 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2000 | 1799 | 0.040 |
Why?
|
| Bone and Bones | 2 | 2007 | 2575 | 0.040 |
Why?
|
| Health Status Indicators | 1 | 2004 | 968 | 0.040 |
Why?
|
| Asthma | 2 | 2009 | 5955 | 0.040 |
Why?
|
| Triiodothyronine, Reverse | 6 | 1985 | 23 | 0.040 |
Why?
|
| Diabetic Nephropathies | 1 | 2005 | 983 | 0.040 |
Why?
|
| Psychometrics | 1 | 2007 | 2999 | 0.040 |
Why?
|
| Stents | 1 | 2010 | 3276 | 0.040 |
Why?
|
| Dexamethasone | 2 | 1975 | 1949 | 0.040 |
Why?
|
| Vasculitis | 1 | 2002 | 521 | 0.040 |
Why?
|
| Synovial Fluid | 1 | 2020 | 394 | 0.040 |
Why?
|
| Transaminases | 1 | 2018 | 199 | 0.040 |
Why?
|
| Homes for the Aged | 2 | 2012 | 260 | 0.040 |
Why?
|
| Warfarin | 1 | 2006 | 1493 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 634 | 0.040 |
Why?
|
| Societies, Medical | 2 | 2008 | 3740 | 0.040 |
Why?
|
| Recovery of Function | 2 | 2013 | 2924 | 0.040 |
Why?
|
| Information Systems | 1 | 1999 | 410 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 1 | 2007 | 2458 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 2000 | 860 | 0.040 |
Why?
|
| Troponin I | 1 | 2001 | 619 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2019 | 546 | 0.040 |
Why?
|
| Animals | 16 | 2018 | 168561 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 3839 | 0.040 |
Why?
|
| Fever | 2 | 2013 | 1612 | 0.040 |
Why?
|
| Colitis, Ulcerative | 1 | 2009 | 1901 | 0.040 |
Why?
|
| Blood | 4 | 1974 | 598 | 0.040 |
Why?
|
| Causality | 1 | 2023 | 1265 | 0.040 |
Why?
|
| Geography | 1 | 2019 | 669 | 0.040 |
Why?
|
| Computational Biology | 1 | 2009 | 3518 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2023 | 1606 | 0.040 |
Why?
|
| Penicillamine | 1 | 2016 | 59 | 0.040 |
Why?
|
| Complement System Proteins | 1 | 1999 | 795 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 2001 | 1179 | 0.030 |
Why?
|
| Hemophilia A | 1 | 2019 | 351 | 0.030 |
Why?
|
| Culture | 1 | 2000 | 632 | 0.030 |
Why?
|
| Crohn Disease | 1 | 2009 | 2301 | 0.030 |
Why?
|
| Infant | 3 | 2013 | 35070 | 0.030 |
Why?
|
| Cerebrovascular Disorders | 2 | 1995 | 1499 | 0.030 |
Why?
|
| Monte Carlo Method | 2 | 2013 | 1254 | 0.030 |
Why?
|
| ROC Curve | 1 | 2024 | 3528 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2020 | 1653 | 0.030 |
Why?
|
| Oleic Acids | 2 | 1986 | 70 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2017 | 688 | 0.030 |
Why?
|
| Child | 7 | 2013 | 77478 | 0.030 |
Why?
|
| Selection Bias | 1 | 1997 | 369 | 0.030 |
Why?
|
| Life Style | 1 | 2007 | 3824 | 0.030 |
Why?
|
| Autoantigens | 1 | 2000 | 891 | 0.030 |
Why?
|
| Hematologic Neoplasms | 1 | 2007 | 1820 | 0.030 |
Why?
|
| Depressive Disorder, Major | 1 | 2013 | 4628 | 0.030 |
Why?
|
| Minocycline | 1 | 2016 | 163 | 0.030 |
Why?
|
| Pancreatitis | 1 | 2002 | 1090 | 0.030 |
Why?
|
| Back Pain | 1 | 2019 | 545 | 0.030 |
Why?
|
| Protein-Energy Malnutrition | 1 | 1975 | 187 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2003 | 2485 | 0.030 |
Why?
|
| Nonprescription Drugs | 1 | 2015 | 116 | 0.030 |
Why?
|
| Patient Admission | 3 | 2009 | 1380 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 3507 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 1979 | 1538 | 0.030 |
Why?
|
| Iodine | 4 | 1970 | 285 | 0.030 |
Why?
|
| Antistreptolysin | 1 | 2013 | 7 | 0.030 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2019 | 445 | 0.030 |
Why?
|
| Endocrinology | 1 | 2000 | 443 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2001 | 971 | 0.030 |
Why?
|
| Alcoholism | 2 | 1984 | 1904 | 0.030 |
Why?
|
| Protein Binding | 8 | 1987 | 9387 | 0.030 |
Why?
|
| Teaching | 1 | 2001 | 1174 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 1998 | 740 | 0.030 |
Why?
|
| Outpatients | 2 | 2011 | 1483 | 0.030 |
Why?
|
| Publication Bias | 1 | 2013 | 161 | 0.030 |
Why?
|
| Cartilage, Articular | 1 | 2020 | 1095 | 0.030 |
Why?
|
| Internal Medicine | 1 | 2000 | 1009 | 0.030 |
Why?
|
| Patient Readmission | 2 | 2019 | 3111 | 0.030 |
Why?
|
| Iodide Peroxidase | 2 | 1992 | 293 | 0.030 |
Why?
|
| Epigenomics | 1 | 2018 | 902 | 0.030 |
Why?
|
| Models, Econometric | 1 | 2013 | 219 | 0.030 |
Why?
|
| Health Services Misuse | 3 | 1990 | 243 | 0.030 |
Why?
|
| American Recovery and Reinvestment Act | 1 | 2012 | 71 | 0.030 |
Why?
|
| Clinical Coding | 1 | 2013 | 171 | 0.030 |
Why?
|
| Antipsychotic Agents | 1 | 2005 | 3058 | 0.030 |
Why?
|
| Communication | 1 | 2006 | 3728 | 0.030 |
Why?
|
| Renal Dialysis | 2 | 2011 | 1780 | 0.030 |
Why?
|
| Kidney Transplantation | 3 | 2011 | 4246 | 0.030 |
Why?
|
| Thyroglobulin | 3 | 1993 | 114 | 0.030 |
Why?
|
| Prolactin | 1 | 1974 | 669 | 0.030 |
Why?
|
| Biological Therapy | 1 | 2013 | 138 | 0.030 |
Why?
|
| Immune Sera | 3 | 1971 | 641 | 0.030 |
Why?
|
| Pain, Postoperative | 1 | 2022 | 1638 | 0.030 |
Why?
|
| Health Planning | 1 | 1993 | 237 | 0.030 |
Why?
|
| Tennessee | 1 | 2011 | 117 | 0.030 |
Why?
|
| Propylthiouracil | 5 | 1982 | 69 | 0.030 |
Why?
|
| Systems Theory | 1 | 2011 | 59 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2010 | 17400 | 0.020 |
Why?
|
| Filgrastim | 1 | 2011 | 132 | 0.020 |
Why?
|
| Dialysis | 3 | 1986 | 75 | 0.020 |
Why?
|
| Naphthalenes | 1 | 2012 | 194 | 0.020 |
Why?
|
| Thyroiditis | 3 | 1973 | 85 | 0.020 |
Why?
|
| Mitral Valve Stenosis | 1 | 2013 | 376 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2021 | 2575 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 1975 | 1470 | 0.020 |
Why?
|
| Complement Fixation Tests | 2 | 1968 | 78 | 0.020 |
Why?
|
| Peritoneal Dialysis | 1 | 2011 | 146 | 0.020 |
Why?
|
| Liver Diseases | 1 | 1979 | 1252 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2011 | 163 | 0.020 |
Why?
|
| Occupational Diseases | 1 | 1999 | 1472 | 0.020 |
Why?
|
| Respiratory Tract Diseases | 1 | 2016 | 722 | 0.020 |
Why?
|
| Orthopedics | 1 | 2000 | 903 | 0.020 |
Why?
|
| Fluvoxamine | 1 | 2010 | 74 | 0.020 |
Why?
|
| Mortality | 2 | 2012 | 2857 | 0.020 |
Why?
|
| Ontario | 1 | 2011 | 381 | 0.020 |
Why?
|
| Pulmonary Edema | 1 | 2013 | 415 | 0.020 |
Why?
|
| Alleles | 2 | 2015 | 6931 | 0.020 |
Why?
|
| Chromatography, Gas | 2 | 1985 | 156 | 0.020 |
Why?
|
| Social Class | 1 | 2019 | 1995 | 0.020 |
Why?
|
| Isoxazoles | 1 | 2011 | 216 | 0.020 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2018 | 1573 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 2557 | 0.020 |
Why?
|
| Membrane Proteins | 2 | 2004 | 7873 | 0.020 |
Why?
|
| Gastrointestinal Tract | 2 | 2006 | 814 | 0.020 |
Why?
|
| Clinical Audit | 1 | 2009 | 31 | 0.020 |
Why?
|
| Organizational Case Studies | 1 | 2010 | 299 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2022 | 4983 | 0.020 |
Why?
|
| Case Management | 1 | 2011 | 286 | 0.020 |
Why?
|
| Vitamin D Deficiency | 1 | 2019 | 1331 | 0.020 |
Why?
|
| Paroxetine | 1 | 2010 | 182 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2013 | 1583 | 0.020 |
Why?
|
| Liver Cirrhosis | 3 | 1976 | 1864 | 0.020 |
Why?
|
| Ulna Fractures | 1 | 2010 | 125 | 0.020 |
Why?
|
| Minnesota | 1 | 2009 | 343 | 0.020 |
Why?
|
| Cost Sharing | 1 | 2012 | 407 | 0.020 |
Why?
|
| Sulfatases | 1 | 1988 | 45 | 0.020 |
Why?
|
| Lidocaine | 1 | 2012 | 542 | 0.020 |
Why?
|
| Nuclear Proteins | 2 | 2003 | 5851 | 0.020 |
Why?
|
| Oleic Acid | 2 | 1986 | 85 | 0.020 |
Why?
|
| Programming Languages | 1 | 2009 | 134 | 0.020 |
Why?
|
| Combined Modality Therapy | 3 | 2008 | 8621 | 0.020 |
Why?
|
| Phospholipids | 1 | 1992 | 781 | 0.020 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2014 | 622 | 0.020 |
Why?
|
| Endoscopy | 2 | 1988 | 1774 | 0.020 |
Why?
|
| Statistics as Topic | 2 | 2008 | 2372 | 0.020 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2011 | 647 | 0.020 |
Why?
|
| Goiter | 4 | 1973 | 86 | 0.020 |
Why?
|
| Antibody Specificity | 2 | 1988 | 1094 | 0.020 |
Why?
|
| Medicare Part C | 1 | 2012 | 296 | 0.020 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 1027 | 0.020 |
Why?
|
| Protein Kinases | 1 | 1975 | 1638 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2023 | 13029 | 0.020 |
Why?
|
| Chromatography, Gel | 4 | 1992 | 668 | 0.020 |
Why?
|
| Receptors, Thyrotropin | 1 | 1987 | 45 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2012 | 1961 | 0.020 |
Why?
|
| Triglycerides | 1 | 2015 | 2450 | 0.020 |
Why?
|
| Acetates | 1 | 1988 | 312 | 0.020 |
Why?
|
| Citalopram | 1 | 2010 | 404 | 0.020 |
Why?
|
| Glucuronidase | 1 | 1988 | 207 | 0.020 |
Why?
|
| Economics, Hospital | 1 | 2009 | 213 | 0.020 |
Why?
|
| Ticlopidine | 1 | 2012 | 899 | 0.020 |
Why?
|
| Emergency Service, Hospital | 2 | 2016 | 7645 | 0.020 |
Why?
|
| Complementarity Determining Regions | 1 | 2007 | 149 | 0.020 |
Why?
|
| Psychoses, Substance-Induced | 1 | 1967 | 96 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 1411 | 0.020 |
Why?
|
| Americas | 1 | 2006 | 111 | 0.020 |
Why?
|
| Diclofenac | 1 | 2006 | 71 | 0.020 |
Why?
|
| Insurance, Physician Services | 1 | 1986 | 24 | 0.020 |
Why?
|
| Thiazoles | 1 | 2013 | 1484 | 0.020 |
Why?
|
| Energy Intake | 1 | 2014 | 2147 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2019 | 3294 | 0.020 |
Why?
|
| Methods | 6 | 1972 | 1128 | 0.020 |
Why?
|
| Computers | 1 | 2009 | 611 | 0.020 |
Why?
|
| Iodine Isotopes | 5 | 1973 | 90 | 0.020 |
Why?
|
| Fluoxetine | 1 | 2010 | 749 | 0.020 |
Why?
|
| Radioligand Assay | 2 | 1984 | 379 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2012 | 1679 | 0.020 |
Why?
|
| Self Administration | 1 | 2007 | 386 | 0.020 |
Why?
|
| Infant, Newborn | 6 | 2013 | 25575 | 0.020 |
Why?
|
| Software | 2 | 2011 | 4434 | 0.020 |
Why?
|
| Benzhydryl Compounds | 1 | 2012 | 840 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 1993 | 1369 | 0.020 |
Why?
|
| Confidentiality | 1 | 2010 | 609 | 0.020 |
Why?
|
| Diuretics | 1 | 2009 | 591 | 0.020 |
Why?
|
| Diagnosis, Differential | 4 | 2013 | 12958 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2018 | 5095 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2011 | 1181 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2007 | 742 | 0.020 |
Why?
|
| Chemical Precipitation | 2 | 1979 | 180 | 0.020 |
Why?
|
| Societies, Scientific | 1 | 2006 | 220 | 0.020 |
Why?
|
| Anxiety | 1 | 2019 | 4279 | 0.020 |
Why?
|
| Respiratory Sounds | 1 | 2009 | 693 | 0.020 |
Why?
|
| Employment | 1 | 2011 | 1124 | 0.020 |
Why?
|
| Angiography | 1 | 1990 | 1636 | 0.020 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2011 | 923 | 0.020 |
Why?
|
| Rabbits | 6 | 1972 | 4886 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2008 | 1003 | 0.020 |
Why?
|
| Arachidonic Acids | 1 | 1985 | 299 | 0.020 |
Why?
|
| Immunization | 4 | 1970 | 1255 | 0.020 |
Why?
|
| Aversive Therapy | 1 | 1984 | 6 | 0.020 |
Why?
|
| Phospholipases | 1 | 1984 | 72 | 0.020 |
Why?
|
| Age of Onset | 1 | 2011 | 3266 | 0.020 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 1990 | 859 | 0.020 |
Why?
|
| Adrenal Glands | 2 | 1968 | 547 | 0.020 |
Why?
|
| Ranitidine | 1 | 2003 | 34 | 0.010 |
Why?
|
| Hypercholesterolemia | 1 | 2011 | 1149 | 0.010 |
Why?
|
| Alcohol Withdrawal Delirium | 1 | 1984 | 27 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 2006 | 683 | 0.010 |
Why?
|
| Foundations | 1 | 2004 | 94 | 0.010 |
Why?
|
| Arachidonic Acid | 1 | 1985 | 434 | 0.010 |
Why?
|
| Urinary Incontinence | 1 | 1988 | 494 | 0.010 |
Why?
|
| Europe | 1 | 2010 | 3339 | 0.010 |
Why?
|
| Social Support | 1 | 1993 | 2117 | 0.010 |
Why?
|
| Thyroiditis, Autoimmune | 4 | 1978 | 101 | 0.010 |
Why?
|
| Fluconazole | 1 | 2003 | 146 | 0.010 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2013 | 1415 | 0.010 |
Why?
|
| Trypsin | 1 | 1984 | 509 | 0.010 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2003 | 102 | 0.010 |
Why?
|
| Personal Health Services | 1 | 1982 | 25 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 12220 | 0.010 |
Why?
|
| Health Care Reform | 1 | 2012 | 1261 | 0.010 |
Why?
|
| Placenta | 1 | 1992 | 1694 | 0.010 |
Why?
|
| Solvents | 1 | 1984 | 302 | 0.010 |
Why?
|
| Taste Threshold | 1 | 1962 | 11 | 0.010 |
Why?
|
| Cell Nucleolus | 1 | 2003 | 166 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1984 | 2191 | 0.010 |
Why?
|
| Amniotic Fluid | 3 | 1979 | 366 | 0.010 |
Why?
|
| Metronidazole | 1 | 2003 | 217 | 0.010 |
Why?
|
| Mutation | 1 | 2007 | 29717 | 0.010 |
Why?
|
| Time and Motion Studies | 1 | 1982 | 149 | 0.010 |
Why?
|
| Continuity of Patient Care | 1 | 2009 | 1048 | 0.010 |
Why?
|
| Centromere | 1 | 2003 | 220 | 0.010 |
Why?
|
| Amiodarone | 1 | 2003 | 212 | 0.010 |
Why?
|
| Electrocardiography | 2 | 2007 | 6440 | 0.010 |
Why?
|
| Reoperation | 1 | 2011 | 4200 | 0.010 |
Why?
|
| Endocrine System Diseases | 1 | 1984 | 248 | 0.010 |
Why?
|
| Long-Term Care | 1 | 1985 | 607 | 0.010 |
Why?
|
| Epitopes | 2 | 2007 | 2569 | 0.010 |
Why?
|
| Psychotic Disorders | 2 | 2005 | 3040 | 0.010 |
Why?
|
| Haplorhini | 3 | 1972 | 551 | 0.010 |
Why?
|
| Adrenal Gland Diseases | 1 | 1962 | 138 | 0.010 |
Why?
|
| Cardiology | 1 | 2012 | 1658 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 6608 | 0.010 |
Why?
|
| Taste | 1 | 1962 | 175 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2001 | 5774 | 0.010 |
Why?
|
| Iodine Radioisotopes | 5 | 1974 | 1030 | 0.010 |
Why?
|
| Echocardiography | 1 | 2013 | 5097 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 2 | 1992 | 305 | 0.010 |
Why?
|
| Adrenal Insufficiency | 1 | 1962 | 184 | 0.010 |
Why?
|
| Sodium Chloride, Dietary | 1 | 1962 | 281 | 0.010 |
Why?
|
| Cell Membrane | 3 | 1976 | 3744 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1962 | 625 | 0.010 |
Why?
|
| Skin Manifestations | 2 | 1970 | 17 | 0.010 |
Why?
|
| Immunoelectrophoresis | 2 | 1971 | 110 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2012 | 3067 | 0.010 |
Why?
|
| Antigens, Nuclear | 1 | 2000 | 192 | 0.010 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1984 | 633 | 0.010 |
Why?
|
| Mood Disorders | 1 | 2005 | 1106 | 0.010 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 1978 | 65 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 2271 | 0.010 |
Why?
|
| Task Performance and Analysis | 1 | 1982 | 780 | 0.010 |
Why?
|
| Intestine, Small | 1 | 1984 | 1243 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1979 | 517 | 0.010 |
Why?
|
| Hospital Costs | 1 | 2003 | 980 | 0.010 |
Why?
|
| Binding, Competitive | 2 | 1975 | 1159 | 0.010 |
Why?
|
| Histocompatibility Antigens | 1 | 1977 | 471 | 0.010 |
Why?
|
| Kinetics | 4 | 1992 | 6474 | 0.010 |
Why?
|
| Fetal Blood | 2 | 1979 | 1317 | 0.010 |
Why?
|
| Delirium | 1 | 1967 | 1608 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 1984 | 1887 | 0.010 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2003 | 1541 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 3862 | 0.010 |
Why?
|
| Methimazole | 2 | 1970 | 41 | 0.010 |
Why?
|
| Fluorescence Polarization Immunoassay | 1 | 1993 | 9 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1984 | 1617 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1979 | 1355 | 0.010 |
Why?
|
| Serum Globulins | 1 | 1972 | 23 | 0.010 |
Why?
|
| Calcium | 1 | 2006 | 5753 | 0.010 |
Why?
|
| Cholic Acids | 1 | 1992 | 40 | 0.010 |
Why?
|
| Immunoglobulins, Thyroid-Stimulating | 2 | 1985 | 34 | 0.010 |
Why?
|
| Liver | 2 | 1984 | 7470 | 0.010 |
Why?
|
| Rats | 3 | 1985 | 24265 | 0.010 |
Why?
|
| Pituitary Hormones, Anterior | 2 | 1961 | 65 | 0.010 |
Why?
|
| Detergents | 1 | 1992 | 230 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 2 | 1988 | 1676 | 0.010 |
Why?
|
| Hemagglutination Inhibition Tests | 2 | 1968 | 77 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1977 | 1382 | 0.010 |
Why?
|
| Binding Sites | 3 | 1976 | 6115 | 0.010 |
Why?
|
| Chromatography | 1 | 1971 | 206 | 0.010 |
Why?
|
| Cytosol | 1 | 1975 | 901 | 0.010 |
Why?
|
| Dementia | 1 | 2005 | 2501 | 0.010 |
Why?
|
| Eye Manifestations | 1 | 1970 | 11 | 0.010 |
Why?
|
| Viscera | 2 | 1961 | 139 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1970 | 326 | 0.010 |
Why?
|
| Ferritins | 1 | 1993 | 590 | 0.010 |
Why?
|
| Pulse | 2 | 1982 | 229 | 0.010 |
Why?
|
| Chromatography, DEAE-Cellulose | 1 | 1969 | 87 | 0.010 |
Why?
|
| Endarterectomy, Carotid | 1 | 1995 | 546 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 1801 | 0.010 |
Why?
|
| Ischemic Attack, Transient | 1 | 1995 | 934 | 0.010 |
Why?
|
| Hemagglutination Tests | 1 | 1968 | 75 | 0.010 |
Why?
|
| Species Specificity | 2 | 1970 | 2479 | 0.010 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1968 | 363 | 0.010 |
Why?
|
| Cellulose | 1 | 1968 | 123 | 0.000 |
Why?
|
| Angiocardiography | 1 | 1987 | 162 | 0.000 |
Why?
|
| Serum Albumin | 2 | 1986 | 674 | 0.000 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 1968 | 205 | 0.000 |
Why?
|
| Sulfates | 1 | 1968 | 390 | 0.000 |
Why?
|
| Mitochondria, Muscle | 1 | 1968 | 171 | 0.000 |
Why?
|
| gamma-Globulins | 1 | 1966 | 124 | 0.000 |
Why?
|
| Oxidative Phosphorylation | 1 | 1968 | 480 | 0.000 |
Why?
|
| Antibody Formation | 1 | 1971 | 1402 | 0.000 |
Why?
|
| Thrombolytic Therapy | 1 | 1995 | 2161 | 0.000 |
Why?
|
| Phospholipases A2 | 1 | 1985 | 202 | 0.000 |
Why?
|
| Prealbumin | 1 | 1986 | 210 | 0.000 |
Why?
|
| Phospholipases A | 1 | 1985 | 216 | 0.000 |
Why?
|
| Carotid Artery Diseases | 1 | 1990 | 882 | 0.000 |
Why?
|
| Muscles | 1 | 1968 | 1617 | 0.000 |
Why?
|
| Angina Pectoris | 1 | 1987 | 977 | 0.000 |
Why?
|
| Immunoassay | 1 | 1966 | 752 | 0.000 |
Why?
|
| Thyroidectomy | 1 | 1968 | 877 | 0.000 |
Why?
|
| Deglutition Disorders | 1 | 1988 | 604 | 0.000 |
Why?
|
| Umbilical Cord | 2 | 1974 | 180 | 0.000 |
Why?
|
| Feminization | 1 | 1962 | 23 | 0.000 |
Why?
|
| Testicular Diseases | 1 | 1962 | 71 | 0.000 |
Why?
|
| Cross Reactions | 2 | 1976 | 841 | 0.000 |
Why?
|
| Private Practice | 1 | 1982 | 154 | 0.000 |
Why?
|
| Disorders of Sex Development | 1 | 1962 | 122 | 0.000 |
Why?
|
| Gonadotropins | 1 | 1962 | 241 | 0.000 |
Why?
|
| Hypersensitivity | 1 | 1969 | 1093 | 0.000 |
Why?
|
| Anticoagulants | 1 | 1995 | 4595 | 0.000 |
Why?
|
| Testis | 1 | 1962 | 800 | 0.000 |
Why?
|
| Electrophoresis | 1 | 1978 | 240 | 0.000 |
Why?
|
| Metabolic Clearance Rate | 1 | 1979 | 379 | 0.000 |
Why?
|
| Uremia | 1 | 1979 | 200 | 0.000 |
Why?
|
| Psychotherapy | 1 | 1967 | 1644 | 0.000 |
Why?
|
| Atrophy | 1 | 1962 | 1576 | 0.000 |
Why?
|
| Chromatography, Affinity | 1 | 1978 | 549 | 0.000 |
Why?
|
| Drug Evaluation | 1 | 1978 | 637 | 0.000 |
Why?
|
| Haploidy | 1 | 1977 | 136 | 0.000 |
Why?
|
| Fatty Acids | 1 | 1985 | 1806 | 0.000 |
Why?
|
| Disease | 1 | 1962 | 681 | 0.000 |
Why?
|
| Cattle | 3 | 1972 | 3923 | 0.000 |
Why?
|
| Reflex, Stretch | 1 | 1974 | 24 | 0.000 |
Why?
|
| Hormones | 1 | 1959 | 884 | 0.000 |
Why?
|
| Chromatography, Thin Layer | 1 | 1973 | 223 | 0.000 |
Why?
|
| Mice | 2 | 1970 | 81045 | 0.000 |
Why?
|
| Fasting | 1 | 1978 | 1589 | 0.000 |
Why?
|
| Achilles Tendon | 1 | 1974 | 152 | 0.000 |
Why?
|
| Injections, Intravenous | 1 | 1974 | 1420 | 0.000 |
Why?
|
| Electroencephalography | 1 | 1967 | 6142 | 0.000 |
Why?
|
| Pituitary Gland | 1 | 1974 | 665 | 0.000 |
Why?
|
| Charcoal | 1 | 1971 | 63 | 0.000 |
Why?
|
| Guinea Pigs | 1 | 1972 | 1386 | 0.000 |
Why?
|
| Myxedema | 1 | 1969 | 17 | 0.000 |
Why?
|
| Sheep | 1 | 1972 | 1437 | 0.000 |
Why?
|
| Chromosome Disorders | 1 | 1972 | 515 | 0.000 |
Why?
|
| Autopsy | 1 | 1973 | 1006 | 0.000 |
Why?
|
| Neoplasm Metastasis | 1 | 1979 | 4839 | 0.000 |
Why?
|
| Dogs | 1 | 1972 | 3910 | 0.000 |
Why?
|
| Immunoglobulins | 1 | 1970 | 880 | 0.000 |
Why?
|
| Serum Albumin, Bovine | 1 | 1967 | 324 | 0.000 |
Why?
|
| Chromosome Aberrations | 1 | 1972 | 1811 | 0.000 |
Why?
|
| Cytoplasm | 1 | 1969 | 1539 | 0.000 |
Why?
|
| Ethanol | 1 | 1969 | 1337 | 0.000 |
Why?
|
| Thyroid Neoplasms | 1 | 1973 | 2274 | 0.000 |
Why?
|
| Adenocarcinoma | 1 | 1973 | 6347 | 0.000 |
Why?
|